Modotuximab
Monoclonal antibody
- none
- 1310460-86-6
- none
- 1W7BD1M08N
- D11125
Modotuximab (INN; formerly zatuximab) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER1.[1]
References
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e